AcelRx Pharmaceuticals, Inc. (ACRX)
Stock Price:
$1.77 USD
-0.02 (-0.84%)
Updated Oct 29, 2020 10:16 AM EDT - Market open
Key Info
| Market Cap |
159.42M |
| Revenue (ttm) |
4.39M |
| Net Income (ttm) |
-49.69M |
| Shares Out |
90.32M |
| EPS (ttm) |
-0.62 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 29, 2020 |
| Last Price |
$1.77 |
| Previous Close |
$1.78 |
| Change ($) |
-0.02 |
| Change (%) |
-0.84% |
| Day's Open |
1.75 |
| Day's Range |
1.71 - 1.80 |
| Day's Volume |
193,907 |
| 52-Week Range |
0.70 - 2.50 |
More Stats
| Market Cap |
159.42M |
| Enterprise Value |
145.94M |
| Earnings Date (est) |
Mar 11, 2021 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
90.32M |
| Float |
87.79M |
| EPS (basic) |
-0.62 |
| EPS (diluted) |
-0.62 |
| FCF / Share |
-0.64 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
8.28M |
| Short Ratio |
2.98 |
| Short % of Float |
9.43% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
36.29 |
| PB Ratio |
n/a |
| Revenue |
4.39M |
| Operating Income |
-51.21M |
| Net Income |
-49.69M |
| Free Cash Flow |
-51.53M |
| Net Cash |
13.49M |
| Net Cash / Share |
0.15 |
| Gross Margin |
-208.92% |
| Operating Margin |
-1,165.67% |
| Profit Margin |
-1,131.00% |
| FCF Margin |
-1,172.89% |
| ROA |
-34.25% |
| ROE |
n/a |
| ROIC |
-58.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (5)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
1 |
Price Target
$4.97*
(181.59% upside)
Low
0.84
Current: $1.77
High
9.00
Target: 4.97
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2.29 | 2.15 | 8.00 | 17.36 | 19.26 | 5.22 | 29.50 | 2.39 | 1.07 | - |
| Revenue Growth | 6.42% | -73.1% | -53.94% | -9.89% | 269.24% | -82.32% | 1132.33% | 123.32% | - | - |
| Gross Profit | -4.52 | -1.83 | -2.66 | 5.04 | 17.49 | 5.22 | 29.50 | 2.39 | 1.07 | - |
| Operating Income | -54.21 | -35.73 | -38.68 | -31.96 | -19.95 | -37.65 | -6.67 | -29.71 | -19.35 | -12.19 |
| Net Income | -53.24 | -47.15 | -51.51 | -43.16 | -24.40 | -33.35 | -23.43 | -33.36 | -20.10 | -14.34 |
| Shares Outstanding | 79.18 | 58.41 | 46.88 | 45.31 | 44.30 | 43.43 | 39.75 | 22.12 | 17.34 | 0.66 |
| Earnings Per Share | -0.67 | -0.81 | -1.10 | -0.95 | -0.60 | -0.91 | -0.59 | -1.51 | -1.16 | -21.84 |
| Operating Cash Flow | -51.18 | -29.08 | -29.77 | -29.40 | -19.95 | -34.46 | -0.49 | -24.58 | -15.29 | -12.23 |
| Capital Expenditures | -3.47 | -0.82 | -2.41 | -3.72 | -1.46 | -5.51 | -3.29 | -0.83 | -2.02 | - |
| Free Cash Flow | -54.65 | -29.89 | -32.17 | -33.12 | -21.41 | -39.96 | -3.77 | -25.41 | -17.31 | -12.23 |
| Cash & Equivalents | 66.14 | 106 | 60.65 | 80.49 | 114 | 75.60 | 104 | 59.97 | 35.99 | 3.89 |
| Total Debt | 29.76 | 11.99 | 19.10 | 21.55 | 20.92 | 24.87 | 14.36 | 15.97 | 19.08 | 12.01 |
| Net Cash / Debt | 36.38 | 93.72 | 41.55 | 58.94 | 92.72 | 50.73 | 89.55 | 44.00 | 16.91 | -8.12 |
| Assets | 91.36 | 121 | 75.55 | 99.99 | 128 | 86.42 | 110 | 64.52 | 40.84 | 6.83 |
| Liabilities | 133 | 116 | 112 | 105 | 94.67 | 39.76 | 36.87 | 30.67 | 23.37 | 16.78 |
| Book Value | -41.42 | 4.25 | -36.51 | -5.34 | 33.11 | 46.66 | 73.16 | 33.85 | 17.47 | -65.89 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
AcelRx Pharmaceuticals, Inc. |
| Country |
United States |
| Employees |
54 |
| CEO |
Vincent J. Angotti |
Stock Information
| Ticker Symbol |
ACRX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—Specialty & Generic |
| Unique Identifier |
NASDAQ: ACRX |
| IPO Date |
February 14, 2011 |
Description
AcelRx Pharmaceuticals, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.